MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim® Therapy for Bowel Control. InterStim Therapy, previously ...

InterStim Therapy is a sacral neuromodulation therapy from Medtronic. InterStim has been regularly used for urinary incontinence for more than a decade, but recently received additional approval as ...

InterStim Therapy for Bowel Control Recently Approved by the U.S. FDA MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. (NYSE: MDT) announced today that newly published data from a multicenter, ...

The FDA has issued Medtronic clearance to market the InterStim sacral nerve stimulation therapy system for people with chronic fecal incontinence. The pacemaker-like device has already been FDA ...

Medtronic MDT recently announced a patent litigation win related to its sacral neuromodulation device and termed it as ‘an important victory’. Specifically, the company’s sacral neuromodulation device ...

(Reuters Health) - Botox injections may be slightly better at reducing urinary incontinence in some older women than InterStim, an implanted bladder control device, results of a U.S. trial suggest.